Fig. 2From: Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanomaImmunohistochemistry performed on two regional CMM lymph node metastases. Expression of protein Ki67 is demonstrated. The upper panel shows a tumor with low proportion (below 25%) of Ki67 staining, while the lower panel shows one with a high proportion (above 25%)Back to article page